Troels Sørensen

Global Head Clinical Practice Boehringer Ingelheim

Troels Sørensen has over 25 years of experience in the pharmaceutical industry with a unique broad profile across gene therapy, biologic, and small molecule specialty care, executing customer-facing and leadership roles in Research, Clinical Operations, Medical Affairs, Sales, Marketing and Commercial Asset/Portfolio evaluation. His passion is equitable population health attainment through the integration of public and private sectors of health systems by the development of common language, measures, and goals along the tactic to impact continuum. He devised the Target Population Output (TPO) measurement, a common tool for public and private stakeholders to align population health and business goals. TPOs have been implemented and refined since 2020. In 2023 TPOs were introduced publicly in the context of the Harvard Health System Innovation Lab’s Strategic Public Private Partnership framework, and in 2024 this was presented, by Harvard, at the World Economic Forum, Davos, in a session hosted by them, Novartis and Novo Nordisk. As global head of Clinical Practice at Boehringer-Ingelheim, Troels continues to work on practical and pragmatic solutions for alignment and goal setting within the pharmaceutical industry to facilitate partnership and integration with health systems. He leads global Medical Affairs Partnerships, Implementation Science and TPO teams. Based in Basel, Switzerland, Troels, has worked for several pharmaceutical companies including Roche, Johnson & Johnson, UCB, AstraZeneca, Takeda and Novartis. He is an alumnus of the European Schools system, Oxford University, the British Medical Research Councils’ National Institute for Medical Research (now The Francis Crick Institute) and Warwick Business School.